Clinical trials: Locally Advanced Head and Neck Carcinoma
Chemoradiation, Nasopharyngeal Carcinoma
Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma
Locally advanced nasopharyngeal carcinoma patients(UICC7th stageIII to IVb) will receive either cisplatin plus 5-fluorouracil (PF) or docetaxel plus cisplatin and 5-fluorouracil(TPF) neoadjuvant chemotherapy with concurrent…
- Trial name
- ESNCCT (NCT01536223)
- Testing
- PF (cisplatin and 5-fluorouracil) group, TPF (docetaxel plus cisplatin and 5-fluorouracil) group
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Cancer
Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer
This is a randomized, open-label investigator initiated pilot/ feasibility study comparing the effectiveness of intra-arterial administration of cisplatin therapy to intravenous administration of cisplatin when each is combined…
- Trial name
- NCT01587820
- Testing
- Intra-arterial cisplatin, Intravenous cisplatin
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Southern Illinois University
Esophageal Cancer
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093652
- Testing
- gefitinib, oxaliplatin, conventional surgery
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Squamous Cell Carcinoma
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
This is a phase 2, single-arm clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade camrelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy and as…
- Trial name
- NCT05213884
- Testing
- Camrelizumab, Concurrent cisplatin chemotherapy, Intensity-modulated radiotherapy (IMRT)
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Chongqing University Cancer Hospital
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002984
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Squamous Cell Carcinoma of the Head and Neck
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
The primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
- Trial name
- NCT04459715
- Testing
- Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT)
- Where
- 288 sites in United States, Argentina and 24 more
- Volunteers
- 730 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Locally Advanced Unresectable Esophageal Cancer
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT
Phase II study of definitive concurrent chemoradiotherapy follows consolidative chemotherapy with S1 for locally advanced unresectable esophageal cancer.
- Trial name
- NCT06598917
- Testing
- S-1
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of…
- Trial name
- NCT07437898
- Testing
- Adebrelimab, chemotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Hospital of Putian University
Head and Neck Cancer
Nutritional Status Assessment in Head and Neck Cancer Patients Receiving Radiotherapy or Chemo-radiotherapy
Radiotherapy and chemotherapy are standard treatment of head and neck cancer alone or associated to surgical treatment. Early (during treatment or the following weeks) and late side effects contribute to malnutrition in this…
- Trial name
- NUTRINECK (NCT02900963)
- Testing
- weekly assessment of patient's weight
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Centre Henri Becquerel
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of MRG003 in Combination With Pucotenlimab Injection ± Cisplatin in Patients With Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06530914
- Testing
- MRG003 combined with Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin
- Volunteers
- 30 people
- Sponsor
- Lei Liu
Esophageal Squamous Cell Carcinoma
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
Esophageal cancer is a kind of disease with high incidence and mortality. Definitive concurrent chemoradiotherapy is an important treatment for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04212598
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Wuhan University
Head and Neck Squamous Cell Carcinoma
A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a non-randomized, phase II, open label study of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules induction chemotherapy in locally advanced squamous cell carcinoma of head and neck patients who…
- Trial name
- NCT03267121
- Testing
- Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium Capsules
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Locally Advanced Head and Neck Squamous Cell Carcinoma
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
This study is a retrospective real-world study. In this study, we plan to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab .
- Trial name
- Redbull-1 (NCT04949503)
- Testing
- nimotuzumab
- Where
- 5 sites in China
- Volunteers
- 1,931 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Esophageal Carcinoma, Neoadjuvant Immunotherapy
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
This prospective study aims to clarify the clinical efficacy and survival prognosis of neoadjuvant immune checkpoint inhibitor (ICI) combined with chemotherapy for esophageal cancer.
- Trial name
- NCT05777707
- Testing
- PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Beijing Friendship Hospital
Nasopharyngeal Carcinoma
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
This trial plans to enroll patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT05097209
- Testing
- Camrelizumab, Gemcitabine, Induction Cisplatin
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Wei Jiang
Squamous Cell Carcinoma of the Head and Neck
Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer
Patients with locally advanced suqamous cell carcinoma of the head and neck region receive a hypoxia scan either by magnetic resonance tomography, computed tomography or fluoromisonidazole (FMISO)-PET-CT.
- Trial name
- NCT02352792
- Testing
- radiochemotherapy with 70 Gy, radiochemotherapy with 77 Gy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- University Hospital Tuebingen
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
This study aims to investigate the safety and efficacy of oral paclitaxel combined with radiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.
- Trial name
- NCT07435454
- Testing
- oral paclitaxel+radiotherapy
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Locally Advanced or Metastatic Malignant Solid Tumors
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
- Trial name
- NCT04225117
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- Astellas Pharma Global Development, Inc.